Hypoxic cytotoxic agents: A new approach to cancer chemotherapy

Drug Resistance Updates

Volumn 3, Issue 1, 2000, Pages 7-13

  Brown, J Martin ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; CYTOTOXIN; TIRAPAZAMINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL KILLING; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECT; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; TARGET CELL; TUMOR SUPPRESSOR GENE;

EID: 0034144552     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0120     Document Type: Article

References (39)

1. Gray L. H., Conger A. D., Ebert M., Hornsey S., Scott O. C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
2. Grau C., Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol. 13:1988;301-309.
3. Simpson-Herren L., Noker P. E., Wagoner S. D. Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol. 22:1988;131-136.
4. Durand R. E. The influence of microenvironmental factors during cancer therapy. In vivo. 8:1994;691-702.
5. Teicher B. A. Hypoxia and drug resistance. Cancer Metastasis Rev. 13:1994;139-168.
6. Mueller-Klieser W., Vaupel P., Manz R., Schmidseder R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys. 7:1981;1397-1404.
7. Raleigh J. A., Calkins-Adams D. P., Rinker L. H. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:1998;3765-3768.
8. Olive P. L., Durand R. E., Le R. J., Olivotto I. A., Jackson S. M. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res. 53:1993;733-736.
9. Vaupel P., Schlenger K., Knoop C., Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51:1991;3316-3322.
10. Nordsmark M., Bentzen S. M., Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncol. 33:1994;383-389.
11. Brizel D. M., Sibley G. S., Prosnitz L. R., Scher R. L., Dewhirst M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
12. Wouters B. G., Brown J. M. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy. Radiat Res. 147:1997;541-550.
13. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-40.
14. Fyles A. W., Milosevic M., Wong R. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 48:1998;149-156.
15. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
16. Graeber T. G., Osmanian C., Jacks T. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
17. Brizel D. M., Scully S. P., Harrelson J. M. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
18. Sundfor K., Lyng H., Rofstad E. K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer. 78:1998;822-827.
19. Tannock I., Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 42:1981;245-248.
20. Teicher B. A., Lazo J. S., Sartorelli A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Research. 41:1981;73-81.
21. Ensley J. F., Jacobs J. R., Weaver A. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 54:1983;811-814.
22. Jaulerry C., Rodriguez J., Brunin F. Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials. Int J Radiat Oncol Biol Phys. 23:1992;483-489.
23. Bourhis J., Pignon J. P. Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy? Hematol Oncol Clin North Am. 13:1999;769-775, vii.
24. Munck J-N., Cvitkovic E., Piekarski J-D. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst. 83:1991;569-575.
25. Grabenbauer G. G., Steininger H., Meyer M. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol. 47:1998;175-183.
26. Iyer V. N., Szybalski W. Mitomycins and porfiromycin: chemical mechanism of activation and crosslinking of DNA. Science. 145:1964;55-58.
27. Rockwell S., Kennedy K. A., Sartorelli A. C. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys. 8:1982;753-755.
28. Brown J. M., Siim B. G. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiol Oncol. 6:1996;22-36.
29. Haffty B. G., Son Y. H., Sasaki C. T. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials [see comments]. Int J Radiat Oncol Biol Phys. 27:1993;241-250.
30. Wang J., Biedermann K. A., Brown J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52:1992;4473-4477.
31. Lloyd R. V., Duling D. R., Rumyantseva G. V., Mason R. P., Bridson P. K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol. 40:1991;440-445.
32. Brown J. M., Lemmon M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Research. 50:1990;7745-7749.
33. Dorie M. J., Brown J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636.
34. Patterson L. H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12:1993;119-134.
35. McKeown S. R., Hejmadi M. V., McIntyre I. A., McAleer J. J. A., Patterson L. H. AQ4N: an alkylaminoanthraquinone N-oxides showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer. 72:1995;76-81.
36. McKeown S. R., Friery O. P., McIntyre I. A., Hejmadi M. V., Patterson L. H., Hirst D. G. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl. 27:1996;S39-42.
37. von Pawel J., von Roemeling R. Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT 1 trial. Proc Amer Soc Clin Oncol. 17:1998;454a.
38. Brown J. M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59:1999;5863-5870.
39. Brown J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 67:1993;1163-1170.